Ian F. Smith - Oct 3, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Director
Signature
/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith
Stock symbol
SLDB
Transactions as of
Oct 3, 2023
Transactions value $
$0
Form type
4
Date filed
10/5/2023, 03:13 PM
Previous filing
Sep 20, 2023
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +15.6K +22.63% 84.4K Oct 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -15.6K -50% $0.00 15.6K Oct 3, 2023 Common Stock 15.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted units convert to common on a one-for-one basis.
F2 The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.